NeuroGenetic Pharmaceuticals Inc   Report issue

For profit Phase 1
Founded: Del Mar CA United States (2009)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2015
NCT02534480
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

ngp 555 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1